Boyapati A, et al. High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response. ACR 2018, abstract L08.
Dure geneesmiddelen in de reumatologie: zijn ze het waard?
aug 2023 | RA, Spondyloartritis